Arcutis Biotherapeutics, Inc. (ARQT) Stock

About Arcutis Biotherapeutics, Inc.

Arcutis Biotherapeutics, Inc. (ARQT) stock trades at $31.20 with a market capitalization of $3.92B. The stock is valued at a price-to-earnings (P/E) ratio of 113.95, price-to-book of 14.89, price-to-sales of 6.78. Over the past 52 weeks the stock has ranged between $19.30 and $32.82, and currently trades 4.9% below its 52-week high.

On profitability, Arcutis Biotherapeutics, Inc. generates a return on equity (ROE) of 15.05%, above the typical market range of roughly 12-15%, return on capital employed of 10.44%, an operating margin of -3.19%, a net profit margin of 6.15%.

Arcutis Biotherapeutics, Inc. by the numbers, 2017–2025

Between 2017 and 2025 Arcutis Biotherapeutics, Inc. reported revenue of $0 rising to $376.0M. Compounded, revenue has grown —% a year over five years, 354.7% over three, 90.9% over the last twelve months. Net profit fell to $-16.0M.

The most recent net margin is 6.15%. On a trailing twelve-month basis to Jun '26, revenue is $464.0M and net profit $28.0M.

Borrowings rose from $1.0M to $6.0M, cash from operations was $-6.0M in the latest year, positive in 0 of the last 9.

Return on equity has averaged -121.7% over five years, and was -8.5% in the most recent year.

The share price itself has compounded at —% a year over five years, —% over three, —% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Arcutis Biotherapeutics, Inc. (ARQT) — frequently asked questions